Skip to main content
OpenTrials
Completed

NCT Number: NCT03723200

Analyzes of Hemorrhagic Obstetric Patients Whose Were Used Fibrinogen

The files of hemorrhagic obstetric patients undergoing surgery and followed in the intensive care unit and using Fibrinogen and blood products were included in the study between January 2015- September 2018 at the Anesthesiology and Reanimation Clinic of SBU Kanuni Sultan Süleyman Training and Research Hospital. Patients under 18 years of age were excluded from the study. In this study, ages, operation types, number of blood and products, the amount of fibrinogen, the results of the hemogram and bleeding parameters, the levels of fibrinogen, the duration of hospital stay and the intensive care unit were recorded.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemorrhage Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–50 year

Sex eligibility

Female

Study type

Observational

Primary location

Kanuni Sultan Suleyman Education and Training Hospital

Istanbul, Kucukcekmece, 34306, Turkey (Türkiye)

About this study

Bleeding is an important event that threatens the patient's life. Too much blood and blood products can be used in massive bleeding. However, unwanted allergic reactions may occur in blood and blood product transfusions. Fibrinogen is the first coagulation factor in coagulopathy. Some studies have shown that when the fibrinogen level falls to <150-200 mg / dl, the bleeding increases dramatically.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Obstetric patients, underwent surgery and followed in ICU
  • Used Fibrinogen and Blood products
  • Over 18 years age

Exclusion criteria

  • Under 18 years age
  • Obstetric patients, underwent surgery but not used Fibrinogen and Blood products

Treatment and study plan

Fibrinogen and blood products

Other

Fibrinogen and blood products

Primary outcomes

  1. Measurement of fibrinogen (mg/L)

    Time frame: 24 hours

    Significant independent predictor for evolution to severe PPH was plasma fibrinogen level.

  2. Measurement of hemoglobin (g/dL)

    Time frame: 24 hours

    Postpartum hemorrhage (PPH) is a major contributor to maternal death and severe maternal morbidity

  3. Amount of fibrinogen consantrates

    Time frame: 24 hours

    in order to avoid PPH

  4. Amount of blood products (unit)

    Time frame: 24 hours

    degree of hemorrhagie

Secondary outcomes

  1. Hospital stay days

    Time frame: 24 hours

    for the recovery time of patients

Sponsors and collaborators

Lead sponsor

Kanuni Sultan Suleyman Training and Research Hospital

Other

Registry information

Official study title

Treatment of Obstetric Hemorrhage With Fibrinogen and Blood Products: Retrospective Analyzes

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Oct 29, 2018
Registry last updated
Oct 30, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.